As per the research conducted by Fast. MR, the report titled “Lipid Injectable Market By Product Type (Intralipid, Liposyn III, Nutrilipid, Cinvanti, Smoflipid, Clinolipid and Others), By Application (Parenteral Nutrition, Parenteral Drug Delivery), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) – Global Market Size, Development, Growth and Demand Forecast, 2018-2027” provides current as well as future analysis of the market by evaluating the major applications, advantages, trends, and challenges. The report dives deeper to produce useful insights into Lipid Injectable Market such as major global regions and key competitors and strategies that can be used for the entry-level player too.
Overview
Lipid injectable have been clinically used as an energy source which provide essential fatty acids and vitamins to hospitalized patients. Intralipid (100% soybean oil: 1.2% egg phospholipid) which is indicated as a source of calories and essential fatty acids for patients requiring parenteral nutrition, was one of the lipid injectable which got approved by U.S. in 1975, after 14 years of safe clinical use in European countries. Nowadays, lipid emulsions are also used for delivering lipid soluble therapeutic agents intravenously, owing to the biocompatible nature of the lipid-based delivery systems. In the current market scenario, manufacturers are focusing on the development of alternative lipids like olive/soy-based formulations, and combination lipids such as soy/olive/fish oil as compared to soybean based lipids, owing to less inflammatory properties, higher antioxidant content, decrease risk of cholestasis. Thus, expected to boost the market growth during the forecast period.
Get Latest Sample for Lipid Injectable Market @ https://www.fastmr.com/request-s/102
Launch of new products with increasing health awareness are expected to propel the lipid injectable market growth
In the current landscape, manufacturers active in the industry are leaning towards more advanced lipid injectable to meet the growing need among malnutrition patients, thus provides lucrative opportunities to retain significant share in the market. For instance, on March 2019, at the 2019 ASPEN Nutrition Science & Practice Conference, Baxter International Inc. announced that it will going to launch Clinolipid (20% olive oil-based Lipid Injectable Emulsion), at the end of the year 2019 in the U.S., in order to improve care for malnourished patients.
Owing to the dynamic market landscape, development of efficient and cost-effective lipid injectable and awareness about these products among healthcare practitioners will be an imperative factor for manufacturers to establish a strong presence in the lipid injectable market. In January 2018, Fresenius Kabi in collaboration with the American Society for Parenteral and Enteral Nutrition (ASPEN) introduced new educational video series which highlight the dosing, preparation and administration of intravenous lipid emulsions (ILE). This video series is designed to educate clinicians to deliver optimal nutrition to the patients. Such educational materials will create awareness among nutritionists & other clinical practitioners which in turn results in increase in adoption of lipid injectable products at a faster pace.
Lipid Injectable Market Regional Analysis
On the basis of region, North America is expected to show leading position in the lipid injectable market followed by Europe. This is attributed to increasing launch of new products by U.S. Food and Drug Administration (FDA). For instance, in November 2017, USFDA approved Heron Therapeutics, Inc.’s drug- Cinvanti (aprepitant) injectable emulsion, which can be delivered through intravenous infusion, for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Cinvanti Is the first and only polysorbate 80-free, intravenous formulation of an nk1 receptor antagonist Indicated for the prevention of acute and delayed CINV.
Asia Pacific also contribute noteworthy growth in lipid injectable market owing to rise in accidental cases and critical illness which is preceded by a physiological deterioration, intense metabolic changes, malnutrition and impaired immune functions. According to the China Health Statistical Yearbook Compiled by the National Health and Family Planning Commission, the number of outpatients in hospitals has increased significantly from 2,483,091,057 in 2012 to 3,197,103,337 in 2016. Unintentional injuries due to falls, motor vehicle traffic crashes, fire/hot objects, or other external causes, represent a large proportion of such emergency department visits.
Key players operating in the lipid injectable markets include Fresenius Kabi, Abbott Laboratories, Pfizer Inc., B. Braun Melsungen AG, Heron Therapeutics Inc., The Medicines Company, Baxter International Inc. and others
Lipid Injectable Market-Taxonomy
By Product Type
-Intralipid
-Liposyn III
-Nutrilipid
-Cinvanti
-Smoflipid
-Clinolipid
-Others
By Application
-Parenteral Nutrition
-Parenteral Drug Delivery
-Others
By Distribution Channel
-Hospital Pharmacies
-Retail Pharmacies
-Online Pharmacies
By Region
-North America
-Europe
-Asia Pacific
-Latin America
-Middle East and Africa
Access Complete Lipid Injectable Market@ https://www.fastmr.com/report/102/lipid-injectable-market
About Us:
FAST.MR is a global market research and business-consulting organization that aims to provide a deep market insight to our clients, which helps them in better decision making in the dynamic environment. We have a team of highly qualified personnel that studies the market in depth to provide our clients with better strategies to stand out in the market.
Contact Us:
Jason Lee
150 State Street, Albany,
New York, USA 12207
+1 (518) 300-1215
Email: sales@fastmr.com
Website: www.fastmr.com
More – https://fastmr.blogspot.com/
Read More – https://marketresearchtab.com/
No comments:
Post a Comment